Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 46% Improvement Relative Risk HCQ  Sánchez-Álvarez et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 375 patients in Spain Lower mortality with HCQ (p=0.005) Sánchez-Álvarez et al., Nefrología, Apr 2020 Favors HCQ Favors control

Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)

Sánchez-Álvarez et al., Nefrología, doi:10.1016/j.nefroe.2020.04.002
Apr 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Analysis of 868 patients on renal replacement therapy. Statistically significant reduction in mortality with HCQ for patients on dialysis (OR 0.47, p=0.005).
No statistically significant change was found for transplant patients (the result is not given but likely the sample size is too small - the number of transplant patients was half the number of dialysis patients).
risk of death, 45.9% lower, RR 0.54, p = 0.005, treatment 322, control 53, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sánchez-Álvarez et al., 27 Apr 2020, retrospective, database analysis, Spain, peer-reviewed, mean age 67.0, 10 authors.
This PaperHCQAll
Situación de la infección por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo. Informe del Registro COVID-19 de la Sociedad Española de Nefrología (SEN)
J Emilio Sánchez-Álvarez, Miguel Pérez Fontán, Carlos Jiménez Martín, Miquel Blasco Pelícano, Carlos Jesús Cabezas Reina, Ángel M Sevillano Prieto, Edoardo Melilli, Marta Crespo Barrios, Manuel Macía Heras, María Dolores Del Pino Y Pino
Nefrología, doi:10.1016/j.nefro.2020.04.002
Introduction: The recent appearance of the SARS-CoV-2 coronavirus pandemic has had a significant impact on the general population. Patients on renal replacement therapy (RRT) have not been unaware of this situation and due to their characteristics they are especially vulnerable. We present the results of the analysis of the COVID-19 Registry of the Spanish Society of Nephrology. Material and methods: The Registry began operating on March 18th, 2020. It collects epidemiological variables, contagion and diagnosis data, signs and symptoms, treatments and outcomes. It is an online registry. Patients were diagnosed with SARS-CoV-2 infection based on the results of the PCR of the virus, carried out both in patients who had manifested compatible symptoms or had suspicious signs, as well as in those who had undergone screening after some contact acquainted with another patient.
Conflicts of interest The authors have no conflicts of interest to declare.
Chen, Liu, Liu, Xu, Xia et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID19), J Zhejiang Univ (Med Sci, doi:10.3785/j.issn.1008-9292.2020.03.03
Ferrey, Choi, Hanna, Chang, Tantisattamo et al., A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease, Am J Nephrol, doi:10.1159/000507417
Garg, Kim, Whitaker, 'halloran, Cummings et al., Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease COVID-NET-2019, 14 States, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6915e3
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int J Antimicrob Agents
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Henry, Lippi, Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Int Urol Nephrol, doi:10.1007/s11255-020-02451-9
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.3785/j.issn.1008-9292.2020.03.03
Kuba, Imai, Rao, Gao, Guo et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med, doi:10.1016/j.cell.2020.02.052
Liu, Huang, Xu, Yang, Qin et al., Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients, medRxiv, doi:10.1101/2020.03.20.20039586
Liu, Zhao, Liu, Xu, Wong et al., T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV, Antiviral Res
Paton, Lee, Xu, Ooi, Cheung et al., Chloroquine for influenza prevention: a randomized, double-blind, placebo controlled trial, Lancet Infect Dis
Sparks, Hiremath, South, Welling, Luther et al., The coronavirus conundrum: ACE2 and hypertension edition, doi:10.1101/2020.03.20.20039586
Vaziri, Pahl, Crum, Norris, Effect of uremia on structure and function of immune system, J Ren Nutr
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Zhu, Xu, Ma, Yang, Guan et al., Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression, Am J Transplant, doi:10.1111/ajt.15869
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop